Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Integrated Genomic Study Uncovers Mutations Linked to Lung Cancer

By LabMedica International staff writers
Posted on 04 Nov 2008
Cancer researchers have integrated DNA sequencing, gene expression, and DNA copy number data in a large-scale genomic study of lung adenocarcinoma that calls attention to several important signaling pathways and suggests new molecular targets for treatment.

Investigators at Harvard University (Cambridge, MA, USA) were members of a large team that participated in a pilot project (the Tumor Sequencing Project or TSP) that investigated how various genomic technologies could be effectively applied and integrated to reveal the molecular underpinnings of lung adenocarcinoma. More...
The report, which appeared in the October 23, 2008, online edition of the journal Nature, presented data obtained from studying 188 primary lung adenocarcinoma samples.

DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Analysis identified 26 genes that were mutated at significantly high frequencies and thus were probably involved in carcinogenesis. While some of these mutations were in genes already linked to lung adenocarcinoma, a substantial number were previously unrecognized. For example, the NF1, ATM, RB1, and APC genes, which had not before been associated with lung cancer, were mutated in a significant portion of the lung tumors analyzed. Mutations were also found that clustered in several groups of related tyrosine kinase genes, including the EGF, EPH, FGF, NTRK, and VEGF receptor gene families. Several of the mutated genes were tumor suppressors that already had been found to be involved in other cancers.

"DNA copy number analysis and gene expression analysis respectively, together with advanced computational methods, helped provide a detailed view of the genomic landscape of lung cancer,” explained contributing author Dr. Matthew Myerson, professor of oncology at Harvard University. "Integrative approaches like these allow us to more clearly pinpoint important genes than a single method alone would. One of the key findings from our study is that some of the newly discovered genes and pathways that are mutated in lung cancer are also known to be defective in other cancers. That gives us hope that targeted therapies could be used across multiple cancer types.”

Related Links:
Harvard University



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.